Roche to Acquire HOOKIPA Pharma for $300M

TL;DR

Roche buying HOOKIPA for $300M cash - big win for their tech!

AI Summary

HOOKIPA Pharma Inc. announced on June 4, 2024, that it has entered into a definitive agreement to be acquired by Roche for $300 million in cash. This acquisition aims to leverage HOOKIPA's proprietary technology platforms for the development of novel immunotherapies.

Why It Matters

This acquisition by a major pharmaceutical company like Roche could significantly accelerate the development of HOOKIPA's innovative cancer and infectious disease therapies, potentially bringing new treatments to patients faster.

Risk Assessment

Risk Level: medium — The acquisition is subject to customary closing conditions, including regulatory approvals, which introduces some uncertainty regarding the completion timeline and finalization of the deal.

Key Numbers

• $300M — Acquisition Price (Cash amount Roche is paying to acquire HOOKIPA Pharma Inc.)

Key Players & Entities

• HOOKIPA Pharma Inc. (company) — Company filing the report and being acquired
• Roche (company) — Acquiring company
• $300 million (dollar_amount) — Cash purchase price for the acquisition
• June 4, 2024 (date) — Date of the earliest event reported and announcement

FAQ

Key Financial Figures

• $0.0001 — e on which registered Common Stock, $0.0001 par value per share HOOK The Nasdaq

Filing Documents

• tm2416401d1_8k.htm (8-K) — 30KB
• tm2416401d1_ex99-1.htm (EX-99.1) — 26KB
• tm2416401d1_img001.jpg (GRAPHIC) — 23KB
• 0001104659-24-068248.txt ( ) — 269KB
• hook-20240604.xsd (EX-101.SCH) — 3KB
• hook-20240604_lab.xml (EX-101.LAB) — 33KB
• hook-20240604_pre.xml (EX-101.PRE) — 22KB
• tm2416401d1_8k_htm.xml (XML) — 4KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On June 4, 2024, HOOKIPA Pharma Inc. (the "Company") issued a press release entitled "HOOKIPA Pharma Announces Updated Phase 2 Clinical Data at the American Society for Clinical Oncology 2024 Annual Meeting." A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated by reference into this Item 7.01. An updated presentation summarizing the data referenced in the press release is also available on the investor relations section of the Company's corporate website at www.ir.hookipapharma.com. The information in this Item 7.01 and Exhibit 99.1 attached hereto is furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

01 Other Events

Item 8.01 Other Events. On June 4, 2024, the Company announced updated results from its Phase 2 clinical trial of HB-200 in combination with pembrolizumab in patients with recurrent/metastatic human papillomavirus 16 positive ("HPV16+") head and neck cancer. Data were presented as of March 29, 2024, and included 46 first line patients with HPV16+, PD-L1 positive, recurrent or metastatic head and neck squamous cell carcinoma. The updated data continue to demonstrate a favorable safety profile of HB-200 in combination with pembrolizumab and promising clinical activity as a first line treatment. HB-200 + pembrolizumab was generally well tolerated. Grade 3 treatment-related adverse events ("TRAEs") were reported in 7 (15%) patients, serious TRAEs in 2 (4%) patients, and TRAEs leading to treatment discontinuation of HB-200 in 2 (4%) patients. No treatment-related deaths were reported. Among 35 evaluable patients, 4 confirmed complete responses, 9 confirmed partial responses, and 11 confirmed stable disease were observed. Notably, among patients with PD-L1 CPS 20 (N=17), objective response rate was 53% (9/17), complete response rate was 18% (3/17), and disease control rate was 82% (14/17). All responses were confirmed per RECIST 1.1. Preliminary progression free survival for the CPS 20 or higher subgroup was 16.3 months. The preliminary overall survival ("OS") rate was 88% at 9 months, and median OS was unreached as of the cutoff date, with 16 of 19 patients still alive. Median follow-up for these patients was 8.4 months.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated June 4, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: June 4, 2024 HOOKIPA Pharma Inc. By: /s/ Joern Aldag Name: Joern Aldag Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR